DISCOVER A SEA OF OPPORTUNITIES
Sea wolves are a unique subspecies of wolves that have adapted to survive in the harsh and delicate ecosystem of the Great Bear Rainforest on Vancouver Island.
The discovery and development of successful therapeutic products and therapies also takes place in a harsh and delicate ecosystem. Only a tiny percentage of scientific ideas that are pursued finally make it as an approved product.
About
We are Sea Wolves Venture Partners. We can help you select the best innovative scientific ideas and develop them into unique pharmaceutical products and therapies that can address major unmet medical needs.
Sea Wolves Venture Partners was founded by Dr. Mark de Boer, an independent biotech entrepreneur who has started several start-up companies in the field of antibody therapeutics and cell therapy.
Sea Wolves Venture Partners provides advisory and management services to selected clients:
o Scientific and corporate due diligence activities for investors
o C-suite management activities for early-stage life science companies
o Board seats
Sea Wolves Venture Partners is also an engine for early-stage life science company creation. We are currently looking for technology and investment opportunities in mRNA therapeutics and cell therapy.
Current investment portfolio
Celmyra Inc.
Celmyra is aiming to become a leader in the in vivo engineering of immune cells. The company has licensed an unique proprietary and clinically validated nanoparticle platform with several USPs over the currently widely used LNPs. Celmyra has programs for in vivo CAR-T products), myeloid cell re-polarization (autoimmune diseases) and, antigen-specific tolerance induction / stimulation of Tregs. All in the fields of autoimmune, metabolic and allergic diseases.
Arcamyra Inc:
Although also a company creation opportunity is a clinical stage company. Arcamyra is developing a novel nanoparticle formulated TLR agonist to revert myeloid suppressor cells and boost tumor-specific T-cell responses. The Company has a FIH study ongoing in Singapore by IM administration with early positive readout. Arcamyra has also submitted an IND in the US to start a phase I/II study for peritoneal carcinomatosis.
FcR Therapeutics B.V.
FcRTx is focused on autoimmune diseases that can benefit from interfering with derailed Fc-receptor biology and is developing a risk-balanced and diverse pipeline of antibody-bases drugs. The Company is currently seeking seed financing to deliver two well defined IND candidates by the end of 2026.
Contact
info@seawolves-vp.com
© Copyright 2026 Sea Wolves Venture Partners | All rights reserved